Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: Implications of treatment duration and tumor volume
- 22 August 2013
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 36 (9) , 1349-1355
Abstract
Background Stereotactic body radiotherapy (SBRT) has been studied in locally recurrent previously-irradiated head and neck cancers; however, the optimum fractionation and patient selection continues to be defined. Methods Patients (n = 132) with locally recurrent head and neck cancer salvaged via SBRT ± cetuximab (median, 44 Gy/5 fractions) from November 2004 to May 2011 were retrospectively reviewed. Disease outcomes and toxicity were analyzed by predictive factors including treatment duration and tumor volume. Results At a median 6-month follow-up (range, 0–55 months), treatment duration 25 cc remained a significant predictor of inferior survival and tumor control, and was associated with significantly more acute toxicity (p = .017) but no difference in late toxicity. Conclusion SBRT ± cetuximab achieves promising tumor control and survival with low rates of acute/late toxicity even for recurrences >25 cc. Prolongations in treatment time may decrease late toxicity at the expense of disease control. © 2014 Wiley Periodicals, Inc. Head Neck 36: 1349–1355, 2014Keywords
This publication has 22 references indexed in Scilit:
- Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Practical Considerations in the Re-Irradiation of Recurrent and Second Primary Head-and-Neck Cancer: Who, Why, How, and How Much?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Salvage Reirradiaton With Stereotactic Body Radiotherapy for Locally Recurrent Head-and-Neck TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation TherapyAmerican Journal of Clinical Oncology, 2011
- Stereotactic Body Radiation Therapy for Head and Neck Tumor: Disease Control and Morbidity OutcomesJournal of Radiation Research, 2011
- Treatment of large stage I–II lung tumors using stereotactic body radiotherapy (SBRT): Planning considerations and early toxicityRadiotherapy and Oncology, 2010
- Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)The Journal of Thoracic and Cardiovascular Surgery, 2010
- Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck RegionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Expanding Role of the Medical Oncologist in the Management of Head and Neck CancerCA: A Cancer Journal for Clinicians, 2008